FDA — authorised 21 January 2021
- Application: NDA212888
- Marketing authorisation holder: VIIV HLTHCARE
- Local brand name: CABENUVA KIT
- Indication: SUSPENSION, EXTENDED RELEASE — INTRAMUSCULAR
- Status: approved
🇺🇸 Cabotegravir long-acting in United States
FDA authorised Cabotegravir long-acting on 21 January 2021
Marketing authorisation
Frequently asked questions
Is Cabotegravir long-acting approved in United States?
Yes. FDA authorised it on 21 January 2021.
Who is the marketing authorisation holder for Cabotegravir long-acting in United States?
VIIV HLTHCARE holds the US marketing authorisation.